Related Experiment Video
Updated: May 20, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment
Morris D Groves1, Ava B Plummer
1Austin Brain Tumor Center, Texas Oncology, Texas, USA. morris.groves@usoncology.com
Abstract:
Outcomes for patients with glioblastoma have improved with the addition of temozolomide (TMZ) chemotherapy to radiation therapy followed by adjuvant TMZ for up to 1 year. Patients often wish to continue chemotherapy after the standard 1-year course. Whether to continue or to stop TMZ is a complex and stressful decision for the patient and family, and the decision should be based on a discussion of the known risks and benefits of each choice.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Therapeutic Drug Monitoring: Overview and Classification
Treatment Resistant Cancers
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

